OnKure Therapeutics Appoints Robbie Alton, Pharm., as Vice President of Clinical Operations
06. Dezember 2022 07:00 ET
|
OnKure, Inc.
BOULDER, Colo., Dec. 06, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
OnKure Therapeutics Appoints Kevin S. Litwiler, Ph.D., as Senior Vice President of DMPK and Clinical Pharmacology
21. Juni 2022 07:00 ET
|
OnKure, Inc.
BOULDER, Colo., June 21, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
OnKure Therapeutics Announces First Patient Dosed in the Phase 1b/2 Nautilus Trial of OKI-179 in Combination with Binimetinib in Patients with Advanced NRAS-Mutated Melanoma
02. Juni 2022 07:00 ET
|
OnKure, Inc.
BOULDER, Colo., June 02, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
OnKure Therapeutics Expands Boulder Footprint with the Opening of a New Research Laboratory
25. April 2022 07:00 ET
|
OnKure, Inc.
BOULDER, Colo., April 25, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
OnKure Therapeutics Announces Promising Preclinical Data on OKI-179 in RAS-Mutated Tumor Models Presented in a Late-Breaking Session at AACR
08. April 2022 13:00 ET
|
OnKure, Inc.
OKI-179 demonstrated chemical synthetic lethality when combined with MEK and BRAF inhibitors in RAS pathway mutated cancer models The Company plans to initiate the OKI-179-230 Phase 1b/2 trial of...
OnKure Therapeutics to Present Late-Breaking Preclinical Data on OKI-179 at the AACR Annual Meeting 2022
08. März 2022 16:30 ET
|
OnKure, Inc.
BOULDER, Colo., March 08, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...
OnKure Therapeutics Appoints Jason Leverone, CPA, as Chief Financial Officer
08. Februar 2022 07:00 ET
|
OnKure, Inc.
BOULDER, Colo., Feb. 08, 2022 (GLOBE NEWSWIRE) -- OnKure, Inc., a clinical-stage biopharmaceutical company discovering and developing the next generation of oncology precision medicines, today...